English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Topline
Pfizer stock slumped Tuesday as the pharmaceutical giant said it expects sales for its Covid-19 vaccine and oral treatment to decline significantly this year, as investors digest a shifting reality for Pfizer with Covid cases and hospitalizations stabilizing and government subsidization of the shots drying up.
Key Facts
Pfizer reported $1.14 earnings per share and $24.3 billion in total revenue over the final three months of 2022, largely beating consensus analyst estimates, but far more pressing to investors was Pfizer’s year-ahead guidance.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
